Comparison of Vitex Agnus Castus with Meloxicam and Placebo in Treatment of Patients with Cyclical Mastalgia

Year 2012, Volume: 14 Issue: 1, 1 - 5, 01.03.2012

İbrahim Aydın Davut Baltacı Serdar Türkyılmaz Mustafa Öncü

Abstract

Background: Mastalgia is classified as cyclic and non-cyclic. Cyclical one constitutesapproximately 60-70% of mastalgia. It is seen between 2 to 3 decades of age, and it usuallyresponds to treatment.Objectives: To compare efficacy of vitex agnus castus (VAC) preparation with meloxicam andplacebo in treatment of mastalgia.Methods: The study was designed as prospective and placebo-controlled clinical trial. Threegroups were constituted. Before grouping, prolactin level was tested for every patient. Thegroup1 enrolled the patients with cyclical mastalgia and high level prolactin. VAC wasadministered to patients from study group1. The second group enrolled the patients with cyclicalmastalgia along with normal prolactin level, and to which meloxicam was given. Third groupwas placebo group, and placebo was applied. Before treatment, VAS (Visual analogue scale)scoring was applied to every patient. Prolactin level was tested for patients from group 1. After3 months of study, VAS scoring was applied to every patient, but only prolactin levels were reevaluated in patients from group1.Results: 95 patients were analyzed; enrolling women aged 19 to 54 years. Intensity of mastalgiadiminished in VAC group 1, 2 more than in placebo group (p

Keywords

Mastalgia, vitex agnus castus, prolactin

Siklik Mastaljili Hastaların Tedavisinde Vitex Agnus Castus Preperatının Meloksikam Ve Plasebo İle Karşılaştırılması

Abstract

Giriş: Mastalji meme ağrısı olup klinik olarak siklik ve siklik olmayan şeklinde sınıflandırılır.Siklik mastalji mastaljilerin yaklaşık %60’ını kapsar. Siklik mastaljiler en sık 20 ve 30 yaşlardagörülür ve genellikle tedaviye iyi cevap verir.Amaç: Vastus Agnus Castus preparasyonunun (VAC) mastalgi ve hiperprolaktinemi üzerineolan etkinliğinin araştırılması amaçlandı.Metot: Araştırma prospektif ve palsebo kontrollü klinik çalışma olarak yapıldı. Hastalar gruplaraayrılmadan önce her hastadan prolaktin seviyesine bakıldı. Hastalar gruplara ayrıldıktan sonraher hastaya tedavi öncesi VAS uygulandı. Grub 1 siklik mastaljisi ve hiperprolaktinemisi olanhastalardan oluştu. Bu hastalara VAC (agnucaston) başlandı. Grup 2 siklik mastaljisi ve normalprolaktin seviyesi olan ve meloksikam 15 mg/gün başlanan hastalardan oluşmuştur. Placebogrubu mastaljisi olan ve prolaktin seviyesi normal olan hastalardan oluştu. 3 aylık tedavi sonrasıher hastaya VAS ve grup 1 için prolactin seviyesine bakıldı.Sonuçlar: Toplam 19–54 yaş arası 95 hastanın analizi yapıldı. VAC alan grupta mastaljininyoğunluğu plasebo grubundan anlamlı ölçüde azaldığı gözlendi (p

Keywords

Mastalji, vitex agnus castus, prolaktin

References

• Plu-Bureau G, Thalabard JC, Sitruk-Ware R, et al. Mastalgia. J Obstet Gynaecol Can. 2006;28(1):49–71.
• Antonio VM, Frederick MD. Clinical management of breast pain: A review. Obstet Gynecol Surv. 2002;57(7):451-61.
• Ader DN, South-Paul J, Adera T, Deuster PA. Cyclical mastalgia: Prevelance and associated health and behaviorioral factors. J Psyhosom Obstet Gynecol. 2001;22:71-6.
• Tavaf-Motamen H, Ader DN, Browne MW, et al. Clinical evaluation of mastalgia. Arch Surg. 1998;133(2):211-3.
• Plu-Bureau G, Thalabard JC, Sitruk-Ware R, et al. Cyclical mastalgia as a marker of breast cancer susceptibility: Results of a case-control study among French women. British Journal of Cancer. 1992;65(6):945-9.
• Halaska M, Beles P, Gorkow C, et al. Chaste tree (Vitex Agnus Castus) Pharmacology and Clinical Indications. Breast. 1999;8(4):175-81.
• Gorkow C, Wuttke W, März RW. Effectiveness of vitex agnus castus preparations. Wien Med Wochenschr. 2002;152(15- 16):364-72.
• Carmichael AR. Can Vitex Agnus Castus be used for the treatment of mastalgia? What is the current Evidence? Evid Based Complement Alternat Med. 2008;5(3):247-50.
• Holland PA, Gateley CA. Drug therapy of mastalgia. What are the options? Drugs. 1994;48(5):709-16.
• Bilichert-Toft M, Watt-Boolsen S. Clinical approach to women with severe mastalgia and therapeutic posibilities. Acta Obstet Gynecol Scand Suppl. 1984;123:185-8.
• Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus)--pharmacology and clinical indications. Phytomedicine. 2003;10(4):348-57.
• Daniele C, Thompson Coon J, Pittler MH, et al. Vitex agnus castus: a systematic review of adverse events. Drug Saf. 2005;28(4):319-32.
• Gataley C. A, Mansel R.E. Management of the painful and nodular breast. British Medical Bulletin. 1991;47(2):284-94.
• Gatalay C, Mansel RE, Maddox PR, et al. Mastalgia refractory to drug treatment. British Journal of Surgery. 1990;77:1110- 12.
• Tschudin S, Huber R. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: Results of a placebo-controlled Komplementarmed Klass. Naturheilkd. 2000;7(3):162-4.
• Millet AV, Dirbas FM. Clinical management of breast pain: a review. Obstet Gynecol Surv. 2002;57(7):451–61.
• Halaska M, Beles P, Gorkow C, et al. Treatment of cyclical mastalgia with a solution containing a Vitex Agnus Castus extract: Results of a placebo-controlled double-blind study. Breast. 1999;8(4):175-81.
• van Die MD, Burger HG, Teede HJ, et al. Vitex agnus-castus (Chaste-Tree/Berry) in the treatment of menopause-related complaints. Altern Complement Med. 2009;15(8):853–62.
• Sliutz G, Speiser P, Schultz AM, Spona J, et al. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res. 1993; 25(5):253–5.
• Parsay S, Olfati F, Nahidi S, et al. Therapeutic Effects of Vitamin E on cyclic mastalgia. Breast Journal. 2009;5(5):510- 4.
• Denneheny CE. The Use of Herbs and Dietary Supplements in Gynecology: An Evidence- Based Review. J. of Midwifery Womens Health. 2006;51(6):402-9.
• Mansel RE. ABC of Breast Diseases. BMJ. 1994;309:866-8.
• Khan SA, Apkarian AV. The characteristics of cyclical and non-cyclical mastalgia: a prospective study using a modified McGill Pain Questionnaire. Breast Cancer Research and Treatment. 2002;75:147-57.